Drugs that contain Daptomycin
1. Cubicin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39071 | CUBIST PHARMS LLC | Anhydro-and isomer-a-21978c cyclic peptides |
Jun, 2016
(7 years ago) | |
| US8058238 | CUBIST PHARMS LLC | High purity lipopeptides |
Nov, 2020
(3 years ago) | |
| US8129342 | CUBIST PHARMS LLC | High purity lipopeptides |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6852689 | CUBIST PHARMS LLC | Methods for administration of antibiotics |
Sep, 2019
(4 years ago) | |
| US6468967 | CUBIST PHARMS LLC | Methods for administration of antibiotics |
Sep, 2019
(4 years ago) | |
| US8003673 | CUBIST PHARMS LLC | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(4 years from now) | |
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Market Authorisation Date: 12 September, 2003
Treatment: Method of treating bacterial infections; Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including t...
Dosage: POWDER;INTRAVENOUS
CUBICIN family patents
2. Cubicin Rf patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER;INTRAVENOUS
CUBICIN RF family patents
3. Daptomycin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357535 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
| US9655946 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
Market Authorisation Date: 21 June, 2021
Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administerin...
Dosage: POWDER;INTRAVENOUS
DAPTOMYCIN family patents
4. Daptomycin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759497 | XELLIA PHARMS APS | Daptomycin formulations |
Aug, 2038
(14 years from now) | |
Market Authorisation Date: 30 January, 2023
Treatment: NA
Dosage: POWDER;INTRAVENOUS
DAPTOMYCIN family patents
5. Dapzura Rt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173189 | BAXTER HLTHCARE CORP | Daptomycin formulations containing a combination of sorbitol and mannitol |
Mar, 2041
(16 years from now) | |
Market Authorisation Date: 25 January, 2022
Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol
Dosage: POWDER;INTRAVENOUS
DAPZURA RT family patents